Literature DB >> 27785710

Diagnostic Accuracy of Transient Elastography for Detecting Liver Fibrosis After Liver Trannsplantation: A Specific Cut-Off Value Is Really Needed?

B Della-Guardia1, A S Evangelista2, G E Felga2, L V Marins2, P R Salvalaggio2, M D Almeida2.   

Abstract

INTRODUCTION: Liver transplant recipients often perform liver biopsy (LB), specially in the context of potentially recurring diseases, such as hepatitis C infection. However, the LB has risks of complications, despite being the gold standard. Transient elastography (TE) is a noninvasive method comparable to the LB to evaluate liver fibrosis in various settings, but its accuracy among transplant recipients is not fully understood.
OBJECTIVE: To determine the accuracy of TE in liver transplant recipients compared with LB to successfully predict liver fibrosis. PATIENTS AND METHODS: Patients who underwent liver transplantation at Hospital Israelita Albert Einstein from 2010 to 2012 and presented with LB indication were also subjected to TE at the time of LB. The medium value of ten successful measurements was kept as a representative of the liver stiffness. The definition of cut-off points was made to ensure specificity of ≥90 % for all fibrosis stages (F0-F4).
RESULTS: LB was performed in 267 patients. TE was not analyzed in only 8 (3 %) due to an elevated body mass index. The optimal liver stiffness cut-off value and diagnostic performance were 8.1 kPa for F ≥ 1, 12.3 kPa for F ≥ 2, 15.1 for F ≥ 3, and 16.7 for F = 4 for all patients and were 8.1 kPa for F ≥ 1, 12.3 kPa for F ≥ 2, 16.5 for F ≥ 3, and 17.6 for F = 4 for patients with hepatitis C.
CONCLUSIONS: TE demonstrated good performance in defining cut-off points for fibrosis on liver histology observed in transplant recipients. The TE can be considered an alternative to LB in post-liver transplantation.

Entities:  

Keywords:  Liver biopsy; Liver transplantation; Transient elastography

Mesh:

Year:  2016        PMID: 27785710     DOI: 10.1007/s10620-016-4349-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

Review 1.  Appropriateness of liver biopsy.

Authors:  T Poynard; V Ratziu; P Bedossa
Journal:  Can J Gastroenterol       Date:  2000-06       Impact factor: 3.522

2.  Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease.

Authors:  Mirella Fraquelli; Cristina Rigamonti; Giovanni Casazza; Dario Conte; Maria Francesca Donato; Guido Ronchi; Massimo Colombo
Journal:  Gut       Date:  2007-01-25       Impact factor: 23.059

3.  Diagnosis of cirrhosis by transient elastography: what is hidden behind misleading results.

Authors:  Mirella Fraquelli; Cristina Rigamonti
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

4.  Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation.

Authors:  Jose A Carrión; Miquel Navasa; Jaume Bosch; Miquel Bruguera; Rosa Gilabert; Xavier Forns
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

5.  Outpatient liver biopsy: how safe is it?

Authors:  G Garcia-Tsao; J L Boyer
Journal:  Ann Intern Med       Date:  1993-01-15       Impact factor: 25.391

6.  Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis.

Authors:  Mireen Friedrich-Rust; Mei-Fang Ong; Eva Herrmann; Volker Dries; Panagiotis Samaras; Stefan Zeuzem; Christoph Sarrazin
Journal:  AJR Am J Roentgenol       Date:  2007-03       Impact factor: 3.959

7.  Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

Authors:  Françoise Imbert-Bismut; Djamila Messous; Vincent Thibault; Vincent Thibaut; Rob B Myers; Annie Piton; Dominique Thabut; Laure Devers; Bernard Hainque; Anne Mercadier; Thierry Poynard
Journal:  Clin Chem Lab Med       Date:  2004-03       Impact factor: 3.694

8.  Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

Authors:  Thierry Poynard; Mona Munteanu; Françoise Imbert-Bismut; Frederic Charlotte; Dominique Thabut; Sophie Le Calvez; Djamila Messous; Vincent Thibault; Yves Benhamou; Joseph Moussalli; Vlad Ratziu
Journal:  Clin Chem       Date:  2004-06-10       Impact factor: 8.327

9.  Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients.

Authors:  Carsten Kamphues; Katharina Lotz; Christoph Röcken; Thomas Berg; Dennis Eurich; Johann Pratschke; Peter Neuhaus; Ulf P Neumann
Journal:  Clin Transplant       Date:  2010 Sep-Oct       Impact factor: 2.863

10.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998

View more
  3 in total

Review 1.  The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature.

Authors:  Max M Puthenpura; Vishal Patel; John Fam; Leon Katz; David S Tichansky; Stephan Myers
Journal:  Obes Surg       Date:  2020-09-26       Impact factor: 4.129

2.  Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.

Authors:  Mohammad Shadab Siddiqui; Michael O Idowu; Katharine Stromberg; Adam Sima; Emily Lee; Samarth Patel; Sophia Ghaus; Carolyn Driscoll; Richard K Sterling; Binu John; Chandra S Bhati
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-06       Impact factor: 11.382

3.  Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis.

Authors:  Mamatha Bhat; Mahmood Tazari; Giada Sebastiani
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.